MedTrace Logo

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-05-02

No results posted yet for this study

Summary

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Stem cells that have been treated in the laboratory to remove lymphocytes may prevent this from happening.

PURPOSE: Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation.

Conditions

Interventions

BIOLOGICAL

graft versus host disease prophylaxis/therapy

PROCEDURE

allogeneic bone marrow transplantation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Richard J. Jones, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Purpose
SUPPORTIVE_CARE

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Primary Completion
2004-05-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003538 on ClinicalTrials.gov